Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology

다국어 초록 (Multilingual Abstract)

Objective: The objective of this study was to examine the current trends in fertility-sparing (FS) treatment for young atypical endometrial hyperplasia (AEH) and endometrial cancer (EC) patients in Japan.
Methods: This study was conducted by the Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology (JSOG) in the 2017–2018 fiscal year. A nationwide, retrospective questionnaire-style survey—as performed. We collected the data of 413 patients from 102 JSOG gynecological cancer registered institutions.
Results: FS treatment was performed with medroxyprogesterone (MPA) (87.2%) or MPA + metformin (11.6%). Pathological complete remission (CR) after initial treatment was achieved in 78.2% of patients. The significant clinicopathological factors correlated to CR after initial treatment were histology (AEH vs. endometrioid carcinoma grade 1 [ECG1]), body mass index (BMI) (<25 vs. ≥25 kg/m2), and treatment period (<6 vs. ≥6 months). ECG1, time to complete remission (TTCR) ≥6 months, maintenance therapy (−), and pregnancy (−) were associated with a significantly higher risk of recurrence on multivariate analysis. The total pregnancy rate was 47%, and the live birth rate was 40.1%. Patients who received infertility treatments showed a higher live birth rate (50.6%) than those who did not (7.7%).
Conclusion: In this survey, we confirmed that FS treatment in Japan is centered on MPA alone and in combination with metformin, and that the treatment efficacy is similar to that reported in previous reports. A multicenter survey study in Japan showed FS treatment for young AEH and EC patients in compliance with the indications is feasible.

참고문헌 (Reference)

1 Li M, "Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility : a systematic review and meta-analysis" 11 : 4005-4021, 2019

2 National Comprehensive Cancer Network, "Uterine neoplasms version 1. 2021: NCCN clinical practice guidelines in oncology (NCCN Guidelines®)" National Comprehensive Cancer Network

3 Gadducci A, "The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer : a debated therapeutic option" 25 : 683-691, 2009

4 Oizumi R, "Sensitivity analysis on the declining population in Japan : effects of prefecture-specific fertility and interregional migration" 17 : e0273817-, 2022

5 Zhou G, "Role of AMP-activated protein kinase in mechanism of metformin action" 108 : 1167-1174, 2001

6 Gallos ID, "Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia : a systematic review and metaanalysis" 207 : 266-, 2012

7 Matsuzaki T, "Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia" 17 : 325-328, 2018

8 Mitsuhashi A, "Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer" 27 : 262-266, 2016

9 Kataoka H, "Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women" 35 : 11-15, 2014

10 Gunderson CC, "Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma : a systematic review" 125 : 477-482, 2012

11 Chen M, "Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer" 132 : 34-38, 2016

12 Ushijima K, "Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women" 25 : 2798-2803, 2007

13 Jalving M, "Metformin : taking away the candy for cancer?" 46 : 2369-2380, 2010

14 Mitsuhashi A, "Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma : trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial(FELICIA trial)" 10 : e035416-, 2020

15 Akira Mitsuhashi ; Yuji Habu ; Tatsuya Kobayashi ; Yoshimasa Kawarai ; Hiroshi Ishikawa ; Hirokazu Usui ; Makio Shozu, "Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients" 대한부인종양학회 30 (30): 1-11, 2019

16 Park JY, "Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer(KGOG 2002)" 49 : 868-874, 2013

17 Wataru Yamagami ; Mikio Mikami ; Satoru Nagase ; Tsutomu Tabata ; Yoichi Kobayashi ; Masanori Kaneuchi ; Hiroaki Kobayashi ; Hidekazu Yamada ; Kiyoshi Hasegawa ; Hiroyuki Fujiwara ; Hidetaka Katabuchi ; Daisuke Aoki, "Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms" 대한부인종양학회 31 (31): 1-21, 2020

18 Wataru Yamagami ; Nobuyuki Susumu ; Takeshi Makabe ; Kensuke Sakai ; Hiroyuki Nomura ; Fumio Kataoka ; Akira Hirasawa ; Kouji Banno ; Daisuke Aoki, "Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?" 대한부인종양학회 29 (29): 1-12, 2018

19 Wang Y, "Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia" 29 : 699-704, 2019

20 Wang CJ, "Fertility-preserving treatment in young women with endometrial adenocarcinoma : a long-term cohort study" 24 : 718-728, 2014

21 백지선 ; 이완호 ; 강우대 ; 김석모, "Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?" 대한산부인과학회 59 (59): 24-31, 2016

22 Simpson AN, "Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin" 133 : 229-233, 2014

23 Oktay K, "Fertility preservation in patients with cancer : ASCO clinical practice guideline update" 36 : 1994-2001, 2018

24 Inoue O, "Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia" 14 : 2-, 2016

25 Duska LR, "Endometrial cancer in women 40 years old or younger" 83 : 388-393, 2001

26 Tamauchi S, "Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer" 44 : 151-156, 2018

27 Kaku T, "Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women : central pathologic review and treatment outcome" 167 : 39-48, 2001

28 Wei J, "Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review" 96 : e8034-, 2017

29 김미경 ; 성석주 ; 박동춘 ; 홍진화 ; 노주원 ; 강순범, "Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study" 대한부인종양학회 31 (31): 1-8, 2020

30 Cancer Information Service, National Cancer Center Japan, "Cancer registry and statistics" National Cancer Center Japan

31 Ruiz MP, "All-cause mortality in young women with endometrial cancer receiving progesterone therapy" 217 : 669-, 2017